达格列净二甲双胍缓释片在中国健康受试者的等效性研究
叶茜 , 刘一乔 , 吴轩宇 , 王一琪 , 李帆 , 李宏宇 , 孟祥云 , 王凤玲
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1231 -1237.
达格列净二甲双胍缓释片在中国健康受试者的等效性研究
Equivalence study of dapagliflozin metformin extended-release tablets in healthy subjects in China
目的: 比较达格列净二甲双胍缓释片在中国健康人体内的生物利用度和生物等效性。方法: 采用 HPLC-MS/ MS 法测定血浆中达格列净及二甲双胍浓度,采用 WinNonlin 软件(8.2 版本)和 SAS 9.4 软件分析生物等效性。结果: 空腹条件下,单剂量口服达格列净二甲双胍缓释片(10 mg/1 000 mg)受试制剂或参比制剂后,血浆中达格列净的 Cmax、AUC0-t、AUC0-∞几何均数比值与 90% 置信区间分别是 109.18%(101.89%~116.99%)、102.17%(99.37%~105.04%)与101.92%(98.94%~104.99%),血浆中二甲双胍的 Cmax、AUC0-t、AUC0-∞几何均数比值与 90% 置信区间分别是 101.85% (96.67%~107.30%)、100.51%(95.36%~105.95%)与 100.03%(94.94%~105.39%)。餐后条件下,单剂量口服达格列净二甲双胍缓释片(10 mg/1 000 mg)受试制剂或参比制剂后,血浆中达格列净的 Cmax、AUC0-t、AUC0-∞几何均数比值与 90% 置信区间分别是 98.27%(88.80%~108.74%)、103.09%(99.17%~107.16%)与103.27%(99.25%~107.45%),血浆中二甲双胍的 Cmax、 AUC0-t、 AUC0-∞几何均数比值与 90% 置信区间分别是 101.81%(98.36%~105.38%)、98.99%(94.45%~103.75%)与 98.94%(94.48%~ 103.61%)。结论: 两种制剂在空腹和餐后给药情况下均生物等效。
AIM: To compare the bioavailability and bioequivalence of dapagliflozin and metformin extended-release tablets in healthy Chinese subjects. METHODS: Plasma concentrations of dapagliflozin and metformin were determined using HPLC-MS/MS. Bioequivalence was analyzed using WinNonlin software (version 8.2) and SAS 9.4. RESULTS: Fasting conditions: After a single oral dose of the test or reference formulation (10 mg/1 000 mg dapagliflozin/metformin ER), the geometric mean ratios (90% confidence intervals) for dapagliflozin wereCmax: 109.18% (101.89%-116.99%); AUC0–t: 102.17% (99.37%-105.04%); AUC0–∞: 101.92% (98.94%-104.99%). For metformin the values wereCmax: 101.85% (96.67%-107.30%); AUC0–t: 100.51% (95.36%-105.95%); AUC0–∞: 100.03% (94.94%-105.39%). Fed conditions: After a single oral dose of the test or reference formulation, the geometric mean ratios (90% confidence intervals) for dapagliflozin were Cmax: 98.27% (88.80%-108.74%), AUC0–t: 103.09% (99.17%-107.16%); AUC0–∞: 103.27% (99.25%-107.45%). For metformin, the values were Cmax: 101.81% (98.36%-105.38%), AUC0–t: 98.99% (94.45%-103.75%), AUC0–∞: 98.94%(94.48%-103.61%). CONCLUSION: The two formulations are bioequivalent under both fasting and fed conditions.
| [1] |
施勇芳, 廖铁军, 邓颖玉, |
| [2] |
中华医学会糖尿病学分会. 中国 2 型糖尿病防治指南: 2020 年版[J].中华糖尿病杂志, 2021, 13(4): 315-409. |
| [3] |
|
| [4] |
国家食品药品监督管理总局. 《以药动学参数为终点评价指标的化学药物仿制药人体生物等效性研究技术指导原则》[S].2016. |
| [5] |
国家食品药品监督管理总局. 化学药物制剂人体生物利用度和生物等效性研究技术指导原则[S].2005. |
| [6] |
AstraZeneca AB. 达格列净二甲双胍缓释片 (Xigduo XR)FDA 原研说明书[Z]. 2022-12. |
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
邓宁, 胡庆芬, 梁彩虹, |
2024 年度安徽省卫生健康科研项目(皖卫函〔2025〕69 号(AH-WJ2024Aa30029))
白求恩·肿瘤临床研究计划(BCF-XD-ZL-20220118-042)
/
| 〈 |
|
〉 |